The absence of selling and strong participation from both mega-passive and quant funds suggests growing confidence in PRAX’s valuation or upcoming catalysts. Traders should monitor for potential upward price pressure and increased liquidity, especially if this reflects broader sector rotation into biotech.
PRAX drugs
PRAX drug pipeline →- ▲ relutrigine 8/10 Filed/PDUFA (NDA under priority review) · PDUFA date Dec 27, 2026
- ▲ ulixacaltamide 8/10 Filed/NDA under FDA review (PDUFA January 29, 2027) · PDUFA date Jan 29, 2027
- ● vormatrigine 5/10 Phase 3
- ◆ elsunersen 4/10 Phase 2/3 (registrational)
- ● PRAX-110 4/10
- 4 more · All PRAX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $330.59entry
- T+1 · 9mo ago −3.74%α −2.83% · $318.22
- T+5 · 8mo ago −6.53%α −5.32% · $309.01
- T+20 · 8mo ago −16.38%α −8.44% · $276.44
- T+60 · 6mo ago +6.05%α −3.27% · $350.60
How similar events traded
Executive Summary
Six major institutional investors significantly increased or established new positions in Praxis Precision Medicines (PRAX) during Q4 2025, collectively adding $660.4M in net new exposure with no notable selling. The cluster is dominated by large passive managers and quant funds, signaling strong institutional conviction in the stock.
Key Financial Metrics
Institutional Positions
Net institutional flow: $660.4M
▲ Buyers (6)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Fidelity | DOUBLED | +3044.3% | $400.5M | $398.2M |
| Morgan Stanley | ADD | +38.3% | $262.3M | $228.2M |
| RenTech | NEW | +0% | $19.5M | $19.5M |
Key Facts
- Fidelity DOUBLED its stake, increasing holdings from 43.2K to 1.36M shares, adding $398.2M in value.
- Morgan Stanley added $228.2M in new exposure, increasing shares by 246.4K.
- RenTech and Two Sigma, both quant funds, initiated new positions totaling $26.3M.
- Norges Bank, a sovereign wealth fund, established a $1.3M position.
- No institutions exited or trimmed holdings in this quarter.
Financial Impact
6 institutions accumulated $660.4M in net new positions, bringing total institutional cluster holdings to $697.8M.
Risk Factors
- Cluster dominated by passive managers (Fidelity, Morgan Stanley, Wells Fargo), which may reduce signal strength compared to active conviction.
- No insider or activist buying confirmed, this could represent index rebalancing rather than fundamental optimism.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-PRAX-2025-Q4 |
Track record
16 reports on PRAX
4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +15.73% at T+60 after the Jun 29, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $317.69 settles Feb 12
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $328.13 settles Feb 11
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $332.97 settles Feb 5
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $262.59 settles Feb 3
- Nov 4, 202612d ago Press Release Neutral 1/10 Entry $262.59 settles Feb 3
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $288.62 settles Jan 27
- Jun 29, 202620w ago 8-K Bearish 6/10 Entry $334.79 to $282.12 ▲ +15.73% +18.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $247.98 to $351.81 ▲ +41.87% +37.47% vs SPY
- Jun 2, 202623w ago Press Release Neutral 1/10 Entry $278.93 to $367.85 ▲ +31.88% +29.38% vs SPY
- May 7, 202627w ago Press Release Bullish 8/10 Entry $333.28 to $305.51 ▼ −8.33% −12.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers